Statistical analysis revealed that there are no significant differences in age, tumor size, tumor grade, status of lymph node metastasis, hormonal receptors, and receiving neoadjuvant chemotherapy between HCMV- and HCMV+ IBC patients. This evidence concerns the gene NR4A1 and neoplasm.